Provided by Tiger Trade Technology Pte. Ltd.

Pasithea Therapeutics Corp.

0.7153
+0.02012.89%
Post-market: 0.7003-0.0150-2.10%19:57 EDT
Volume:1.55M
Turnover:1.06M
Market Cap:23.90M
PE:-0.36
High:0.7397
Open:0.6960
Low:0.6500
Close:0.6952
52wk High:2.06
52wk Low:0.2810
Shares:33.41M
Float Shares:10.20M
Volume Ratio:3.66
T/O Rate:15.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9764
EPS(LYR):-2.9100
ROE:-58.22%
ROA:-31.49%
PB:0.44
PE(LYR):-0.25

Loading ...

Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis

TIPRANKS
·
Yesterday

Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?

Simply Wall St.
·
May 24

Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained

TIPRANKS
·
May 21

Pasithea Therapeutics Q1 EPS $(0.12) Beats $(0.45) Estimate

Benzinga
·
May 16

Pasithea Therapeutics Corp reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
May 16

Pasithea net loss narrows 19.5% to $2.87 million in Q1 2026

Reuters
·
May 16

Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
May 12

Pasithea Therapeutics files Form 3 for Chief Medical Officer Kartik Krishnan

Reuters
·
May 06

Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives

TIPRANKS
·
May 05

Pasithea Therapeutics names Kartik Krishnan chief medical officer

Reuters
·
May 04

Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 21

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

GlobeNewswire
·
Apr 20

Pasithea Therapeutics files Form 3 beneficial ownership statement for Coastlands Capital LP

Reuters
·
Apr 18

Pasithea Therapeutics Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Apr 03

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

GlobeNewswire
·
Apr 01

Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
Apr 01

Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock

Simply Wall St.
·
Mar 25

Pasithea Therapeutics Corp expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
Mar 21

Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice

TIPRANKS
·
Feb 21